Injectable testosterone undecanoate for the treatment of hypogonadism

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 13, 2014, Pages 1903-1926

  Corona, Giovanni ^a   Maseroli, Elisa ^b   Maggi, Mario ^b  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Erectile dysfunction; Obesity; Testosterone undecanoate; Weight loss

Indexed keywords

ANDROGEN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ANALOGS AND DERIVATIVES; BODY MASS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HUMAN; HYPOGONADISM; INTRAMUSCULAR DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PENIS ERECTION;

ANDROGENS; BODY MASS INDEX; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; PENILE ERECTION; TESTOSTERONE;

EID: 84905866664     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.944896     Document Type: Article

References (126)

1. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013;10:245-84
2. Corona G, Rastrelli G, Vignozzi L, et al. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012;14:251-9
3. Corona G, Rastrelli G, Vignozzi L, Maggi M. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs 2012;17:239-59
4. Nieschlag E, Nieschlag S. Testosterone deficiency: a historical perspective. Asian J Androl 2014;16:161-8
5. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-6
6. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-14
7. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
8. Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002;8:440-56
9. Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013;27:557-79
10. Yin AY, Htun M, Swerdloff RS, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new selfemulsifying formulation. J Androl 2012;33:190-201
11. Muchow M, Maincent P, Müller RH, Keck CM. Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm 2011;37:8-14
12. Behre HM, Abshagen K, Oettel M, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999;140:414-19
13. Nieschlag E, Büchter D, Von Eckardstein S, et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999;51:757-63
14. Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014;11:1577-92
15. Corona G, Jannini EA, Vignozzi L, et al. The hormonal control of ejaculation. Nat Rev Urol 2012;9:508-19
16. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002;23:419-25
17. Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89:5429-34
18. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005;6:1751-9
19. Saad F, Kamischke A, Yassin A, et al. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 2007;9:291-7
20. Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10:579-88
21. Morgentaler A, Dobs AS, Kaufman JM, et al. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. J Urol 2008;180:2307-13
22. Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl 2010;31:457-65
23. Edelstein D, Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother 2010;11:2095-106
24. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008 the Cochrane Collaboration]. 2008. Available from: www.cochranehandbook. org
25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
26. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
27. Minnemann T, Schubert M, Hübler D, et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 2007;10:155-8
28. Minnemann T, Schubert M, Freude S, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 2008;31:718-23
29. Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007;53:353-7
30. Agledahl I, Hansen JB, Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest 2008;68:641-8
31. Agledahl I, Brodin E, Svartberg J, Hansen JB. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Thromb Haemost 2009;102:945-50
32. Giltay EJ, Haider A, Saad F, Gooren LJ. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Andrologia 2008;40:398-400
33. Kalinchenko S, Vishnevskiy EL, Koval AN, et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008;11:57-61
34. Kurbatov D, Kuznetsky J, Traish A. Testosterone improves erectile function in hypogonadal patients with venous leakage. J Androl 2008;29:630-7
35. Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29:102-5
36. Svartberg J, Agledahl I, Figenschau Y, et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20:378-87
37. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27
38. Jockenhövel F, Minnemann T, Schubert M, et al. Comparison of longacting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol 2009;160:815-19
39. Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009;161:443-9
40. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebocontrolled study. J Sex Med 2010;7:3495-503
41. Fennell C, Sartorius G, Ly LP, et al. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf) 2010;73:102-9
42. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572-82
43. Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the doubleblinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602-12
44. Moon DG, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 2010;7:2253-60
45. Permpongkosol S, Tantirangsee N, Ratana-olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med 2010;7:3765-74
46. García JA, Sanchez PE, Fraile C, Escovar P. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Andrologia 2011;43:293-6
47. Arafa M, Zohdy W, Aboulsoud S, Shamloul R. Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus. Andrologia 2012;44(Suppl 1):756-63
48. Ho CC, Tong SF, Low WY, et al. A randomized, double-blind, placebocontrolled trial on the effect of longacting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012;110:260-5
49. Tong SF, Ng CJ, Lee BC, et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian J Androl 2012;14:604-11
50. Aversa A, Bruzziches R, Francomano D, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 2012;15:96-102
51. Hoyos CM, Yee BJ, Phillips CL, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012;167:531-41
52. Jo DG, Lee HS, Joo YM, Seo JT. Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. Yonsei Med J 2013;54:1331-5
53. Ko YH, Moon du G, Moon KH. Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World J Mens Health 2013;31:47-52
54. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975-81
55. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 2014;68:314-29
56. Tan WS, Low WY, Ng CJ, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int 2013;111:1130-40
57. Tirabassi G, Delli Muti N, Corona G, et al. Androgen receptor gene CAG repeat polymorphism independently influences recovery of male sexual function after testosterone replacement therapy in postsurgical hypogonadotropic hypogonadism. J Sex Med 2014;11:1302-8
58. Tirabassi G, Delli Muti N, Corona G, et al. Androgen receptor gene CAG repeat polymorphism regulates the metabolic effects of testosterone replacement therapy in male postsurgical hypogonadotropic hypogonadism. Int J Endocrinol 2013;2013:816-740
59. Francomano D, Bruzziches R, Barbaro G, et al. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 2014;37:401-11
60. Francomano D, Ilacqua A, Bruzziches R, et al. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167-73
61. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014;2014:527470
62. Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612-27
63. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11(6):1567-76
64. Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-A systematic review. Eur Urol 2014;65:99-112
65. Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014;68:203-15
66. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesityassociated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013;168:829-43
67. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012;8:131-43
68. Corona G, Rastrelli G, Silverii A, et al. The identification of prediabetes condition with ARIC algorithm predicts long-term CV events in patients with erectile dysfunction. J Sex Med 2013;10:1114-23
69. Corona G, Rastrelli G, Balercia G, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med 2012;9:1669-80
70. Corona G, Giorda CB, Cucinotta D, et al. The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest 2013;3:864-8
71. Corona G, Giorda C, Cucinotta D, et al. Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors. J Sex Med 2014;11:2065-73
72. Corona G, Mannucci E, Petrone L, et al. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007;4(4 Pt 1):1038-45
73. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014;2014:683515
74. Michalakis K, Mintziori G, Kaprara A, et al. The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism 2013;62:457-78 . An excellent review on obesity-related male HG
75. Morelli A, Comeglio P, Sarchielli E, et al. Negative effects of high glucose exposure in human gonadotropinreleasing hormone neurons. Int J Endocrinol 2013;2013:684659
76. Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009;6:3274-88
77. Morelli A, Sarchielli E, Comeglio P, et al. Metabolic syndrome induces inflammation and impairs gonadotropinreleasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol 2014;382:107-19
78. Morelli A, Comeglio P, Filippi S, et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012;132:80-92
79. Morelli A, Fibbi B, Marini M, et al. Dihydrotestosterone and leptin regulate gonadotropin-releasing hormone (GnRH) expression and secretion in human GnRH-secreting neuroblasts. J Sex Med 2009;6:397-407
80. Morelli A, Marini M, Mancina R, et al. Sex steroids and leptin regulate the "first Kiss" (KiSS 1/G-protein-coupled receptor 54 system) in human gonadotropinreleasing-hormone-secreting neuroblasts. J Sex Med 2008;5:1097-113
81. Morelli A, Comeglio P, Sarchielli E, et al. Negative effects of high glucose exposure in human gonadotropinreleasing hormone neurons. Int J Endocrinol 2013;2013:684659
82. Costanzo PR, Suärez SM, Scaglia HE, et al. Evaluation of the hypothalamic-pituitary-gonadal axis in eugonadal men with type 2 diabetes mellitus. Andrology 2014;2:117-24
83. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2011;34(6 Pt 1):528-40
84. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011;8:272-83
85. Cai X, Tian Y, Wu T, et al. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl 2014;16:146-52
86. Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 2014;11:840-56
87. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-85
88. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-93
89. Monroe AK, Dobs AS. The effect of androgens on lipids. Curr Opin Endocrinol Diabetes Obes 2013;20:132-9
90. Haring R, Baumeister SE, Völzke H, et al. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil 2011;18:86-96
91. Haring R, Xanthakis V, Coviello A, et al. Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study. Int J Androl 2012;35:775-82
92. Corona G, Boddi V, Balercia G, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010;7(4 Pt 1):1547-56
93. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and metaanalysis of randomized controlled trials. BMC Med 2013;11:57
94. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75
95. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: european prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007;116:2694-701
96. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a metaanalytic study. Eur J Endocrinol 2011;165:687-701
97. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-19
98. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011;97:870-5
99. Corona G, Rastrelli G, Maseroli E, et al. Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology 2014; In press
100. Corona G, Rastrelli G, Monami M, et al. Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med 2011;8:2098-105
101. Corona G, Mannucci E, Lotti F, et al. Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED. J Sex Med 2009;6:285-93
102. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22
103. Vigen R, O'Donnell CI, Barön AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-36
104. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:e85805
105. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-7
106. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and metaanalysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:29-39
107. Fernändez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75
108. Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108
109. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone boosting medications: a systematic review and meta-analysis. Exp Opin Saf Drug 2014; in press
110. Morgentaler AD for the Androgen Study Group. Letter to JAMA asking for retraction of misleading article on testosterone therapy. Available at: http://www.androgenstudygroup.org/component/content/article?id=90: letterto-jama-asking-for-retraction-ofmisleading-article-on-testosterone- therapy. [Last accessed 23 July 2014]
111. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2014;17:132-43
112. Rastrelli G, Corona G, Vignozzi L, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med 2013;10:2518-28
113. Vignozzi L, Gacci M, Cellai I, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013;73:789-800
114. Vignozzi L, Rastrelli G, Corona G, et al. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest 2014; [Epub ahead of print]
115. Corona G, Vignozzi L, Rastrelli G, et al. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol 2014;2014:329456
116. Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101-6
117. Corona G, Gacci M, Maseroli E, et al. Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. Asian J Androl 2014; [Epub ahead of print]
118. Vignozzi L, Maggi M. Prostate cancer: intriguing data on inflammation and prostate cancer. Nat Rev Urol 2014;11(7):369-70
119. Maggi M, Schulman C, Quinton R, et al. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med 2007;4(4 Pt 1):1056-69
120. Mackey MA, Conway AJ, Handelsman DJ. Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 1995;10:862-5
121. Available from:http:/www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/reproductivehealthdrugs advisorycommittee/ ucm348092.pdf
122. Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475-88
123. Corona G, Boddi V, Lotti F, et al. The relationship of testosterone to prostatespecific antigen in men with sexual dysfunction. J Sex Med 2010;7(1 Pt 1):284-92
124. Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest 2011;34:232-43
125. Maneschi E, Morelli A, Filippi S, et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol 2012;215:347-62
126. Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 2013;31:103-25